Healthtech Late Stage Investors & VC Firms

847 firms in this list, with a median first check of $1M. 197 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
AT ATW Partners ARKPIBJL15 people · Follows rounds	88🔒	New York	US	Seed–Late Stage	—	+ Add to CRM
AD ADQ MH1 person · Follows rounds	88🔒	Abu Dhabi	AE	Growth–Late Stage	—	+ Add to CRM
AM Amplitude Venture Capital MMAGBSDM16 people · Follows rounds	88🔒	Montreal	CA	Seed–Late Stage	—	+ Add to CRM
B- B-FLEXION APNLSAFW13 people	88🔒	St. Helier	US	Seed–Late Stage	$500K	+ Add to CRM
BR Bridge Bank BCBLDMDB16 people	88🔒	San Francisco	US	Seed–Late Stage	—	+ Add to CRM
IN Infinitas Capital RLSLACAL16 people	88🔒	—		Pre-Seed–Late Stage	—	+ Add to CRM
IN International Finance Corporation MDAGEBET12 people · Follows rounds	88🔒	Washington D.C.	US	Seed–Late Stage	$20M – $500M	+ Add to CRM
KI Kiraboshi Capital	88🔒	Tokyo	JP	Pre-Seed–Late Stage	—	+ Add to CRM
DE Detong Capital JTRSSJTL11 people	88🔒	Shanghai	CN	Seed–Late Stage	$20M	+ Add to CRM
NU Nueterra Capital DTJTBTEE6 people	88🔒	Leawood	US	Seed–Late Stage	—	+ Add to CRM
OR ORI Capital SSDTGSYE15 people	88🔒	Hong Kong	HK	Pre-Seed–Late Stage	—	+ Add to CRM
TE Texas Ventures ESACAVHM6 people	88🔒	Houston	US	Seed–Late Stage	—	+ Add to CRM
VI Vistara Growth RGKBNSJO15 people · Follows rounds	88🔒	Vancouver	CA	Growth–Late Stage	—	+ Add to CRM
GI Gimv AJLTMMPV11 people · Leads rounds	88🔒	The Hague	BE	Growth–Late Stage	$21M – $430M	+ Add to CRM
MV MVM Life Science Partners EBEFHHJT11 people	88🔒	London	GB	Seed–Late Stage	$20M – $100M	+ Add to CRM
IS ISA Ventures EE1 person	88🔒	Cedar Rapids	US	Pre-Seed–Late Stage	$25K – $1M	+ Add to CRM
JS JStar Capital Investments EPJLBBDD13 people	88🔒	Austin	US	Seed–Late Stage	—	+ Add to CRM
GL Global BioAccess Fund BRLWLWTM11 people	88🔒	New York	US	Series A–Late Stage	$10M	+ Add to CRM
VE Veritas Capital	88🔒	New York	US	Growth–Late Stage	—	+ Add to CRM
VI Viola Credit AGEFIVAB12 people · Follows rounds	88🔒	London	GB	Pre-Seed–Late Stage	$2M – $50M	+ Add to CRM
PO Polaris Capital Group Leads rounds	88🔒	Tokyo	JP	Growth–Late Stage	—	+ Add to CRM
SH Shepherd Ventures GCRPTSFD6 people · Leads rounds	88🔒	San Diego	US	Series A–Late Stage	$750K – $3M	+ Add to CRM
TA Tappan Hill Ventures CELMWSMM5 people	88🔒	Ann Arbor	US	Pre-Seed–Late Stage	$100K	+ Add to CRM
CH Cheyenne Ventures GEJFJBRL4 people · Leads rounds	88🔒	Woodside	US	Series A–Late Stage	—	+ Add to CRM

ATW Partners

New YorkSeed–Late Stage

ARKPIBJL15 people

ADQ

Abu DhabiGrowth–Late Stage

MH1 person

Amplitude Venture Capital

MontrealSeed–Late Stage

MMAGBSDM16 people

B-FLEXION

St. HelierSeed–Late Stage$500K

APNLSAFW13 people

Bridge Bank

San FranciscoSeed–Late Stage

BCBLDMDB16 people

Infinitas Capital

Pre-Seed–Late Stage

RLSLACAL16 people

International Finance Corporation

Washington D.C.Seed–Late Stage$20M – $500M

MDAGEBET12 people

Kiraboshi Capital

TokyoPre-Seed–Late Stage

Detong Capital

ShanghaiSeed–Late Stage$20M

JTRSSJTL11 people

Nueterra Capital

LeawoodSeed–Late Stage

DTJTBTEE6 people

ORI Capital

Hong KongPre-Seed–Late Stage

SSDTGSYE15 people

Texas Ventures

HoustonSeed–Late Stage

ESACAVHM6 people

Vistara Growth

VancouverGrowth–Late Stage

RGKBNSJO15 people

Gimv

The HagueGrowth–Late Stage$21M – $430M

AJLTMMPV11 people

MVM Life Science Partners

LondonSeed–Late Stage$20M – $100M

EBEFHHJT11 people

ISA Ventures

Cedar RapidsPre-Seed–Late Stage$25K – $1M

EE1 person

JStar Capital Investments

AustinSeed–Late Stage

EPJLBBDD13 people

Global BioAccess Fund

New YorkSeries A–Late Stage$10M

BRLWLWTM11 people

Veritas Capital

New YorkGrowth–Late Stage

Viola Credit

LondonPre-Seed–Late Stage$2M – $50M

AGEFIVAB12 people

Polaris Capital Group

TokyoGrowth–Late Stage

Shepherd Ventures

San DiegoSeries A–Late Stage$750K – $3M

GCRPTSFD6 people

Tappan Hill Ventures

Ann ArborPre-Seed–Late Stage$100K

CELMWSMM5 people

Cheyenne Ventures

WoodsideSeries A–Late Stage

GEJFJBRL4 people

Data sourced from public filings and firms' own websites — see our methodology.